Citigroup
UBX

Citigroup’s Unity Biotechnology UBX Stock Holding History

Citigroup’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,076
Closed -$23K – 6672
2022
Q1 		$23K Buy
+2,076
New +$23.3K ﹤0.01% 5086
2021
Q4 		– Sell
-295
Closed -$9K – 6101
2021
Q3 		$9K Sell
295
-2,666
-90% -$94.1K ﹤0.01% 5501
2021
Q2 		$137K Buy
2,961
+320
+12% +$15.4K ﹤0.01% 4401
2021
Q1 		$159K Buy
2,641
+338
+15% +$23K ﹤0.01% 4127
2020
Q4 		$121K Buy
2,303
+573
+33% +$27.6K ﹤0.01% 5386
2020
Q3 		$59K Buy
1,730
+49
+3% +$3.1K ﹤0.01% 5486
2020
Q2 		$146K Sell
1,681
-135
-7% -$10K ﹤0.01% 5259
2020
Q1 		$105K Buy
1,816
+28
+2% +$1.76K ﹤0.01% 5302
2019
Q4 		$129K Buy
1,788
+676
+61% +$47.7K ﹤0.01% 5536
2019
Q3 		$68K Sell
1,112
-390
-26% -$27.6K ﹤0.01% 5937
2019
Q2 		$143K Buy
1,502
+464
+45% +$39.5K ﹤0.01% 5551
2019
Q1 		$84K Buy
1,038
+379
+58% +$43K ﹤0.01% 5915
2018
Q4 		$107K Buy
659
+520
+374% +$69K ﹤0.01% 5600
2018
Q3 		$23K Buy
139
+66
+90% +$10.9K ﹤0.01% 7020
2018
Q2 		$11K Buy
+73
New +$10.7K ﹤0.01% 7158

Other funds holding UBX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's UBX Position: Q2 2022 in Review

Citigroup sold out of Unity Biotechnology (UBX) in Q2 2022, closing a stake of 2,076 shares — an estimated $23K sold.

Citigroup first reported a position in UBX in Q2 2018 and held it in 15 quarters. The position peaked at $159K in Q1 2021. 65 funds tracked by Wall St. Rank hold UBX as of Q2 2022.

  • Citigroup reported no remaining Unity Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Citigroup sold 2,076 Unity Biotechnology shares in Q2 2022, an estimated $23K.
  • Citigroup first reported a position in Unity Biotechnology in Q2 2018 and held it in 15 quarters.
  • Citigroup's Unity Biotechnology position peaked at $159K in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2022.

Based on Citigroup's 13F filing for Q2 2022, filed 10 Aug 2022.